Transdermal and Topical Drug Administration in the Treatment of Pain

Wojciech Leppert, Malgorzata Malec-Milewska, Renata Zajaczkowska, Jerzy Wordliczek, Wojciech Leppert, Malgorzata Malec-Milewska, Renata Zajaczkowska, Jerzy Wordliczek

Abstract

The comprehensive treatment of pain is multidimodal, with pharmacotherapy playing a key role. An effective therapy for pain depends on the intensity and type of pain, the patients' age, comorbidities, and appropriate choice of analgesic, its dose and route of administration. This review is aimed at presenting current knowledge on analgesics administered by transdermal and topical routes for physicians, nurses, pharmacists, and other health care professionals dealing with patients suffering from pain. Analgesics administered transdermally or topically act through different mechanisms. Opioids administered transdermally are absorbed into vessels located in subcutaneous tissue and, subsequently, are conveyed in the blood to opioid receptors localized in the central and peripheral nervous system. Non-steroidal anti-inflammatory drugs (NSAIDs) applied topically render analgesia mainly through a high concentration in the structures of the joint and a provision of local anti-inflammatory effects. Topically administered drugs such as lidocaine and capsaicin in patches, capsaicin in cream, EMLA cream, and creams containing antidepressants (i.e., doxepin, amitriptyline) act mainly locally in tissues through receptors and/or ion channels. Transdermal and topical routes offer some advantages over systemic analgesic administration. Analgesics administered topically have a much better profile for adverse effects as they relieve local pain with minimal systemic effects. The transdermal route apart from the above-mentioned advantages and provision of long period of analgesia may be more convenient, especially for patients who are unable to take drugs orally. Topically and transdermally administered opioids are characterised by a lower risk of addiction compared to oral and parenteral routes.

Keywords: adverse effects; analgesics; pain; topical drugs; transdermal opioids.

Conflict of interest statement

All authors declare no conflict of interests.

Figures

Figure 1
Figure 1
Transdermal application for systemically acting drugs.
Figure 2
Figure 2
Topical application for locally acting drugs.

References

    1. Mc Cleane G.T. Pain Management: Expanding the Pharmacological Options. Wiley-Blackwell Publishing; Hoboken, NJ, USA: 2008.
    1. Argof C.E. Topical Analgesics in the Management of Acute and Chronic Pain. Mayo Clin. Proc. 2013;88:195–205. doi: 10.1016/j.mayocp.2012.11.015.
    1. Leppert W., Krajnik M., Wordliczek J. Delivery Systems of Opioid Analgesics for Pain Relief: A Review. Curr. Pharm. Des. 2013;19:7271–7293. doi: 10.2174/138161281941131219130127.
    1. Pergolizzi J.V., Jr., Mercadante S., Echaburu A.V., Van den Eynden B., Fragoso R.M., Mordarski S., Lybaert W., Beniak J., Orońska A., Slama O., et al. The role of transdermal buprenorphine in the treatment of cancer pain: An expert panel consensus. Curr. Med. Res. Opin. 2009;25:1517–1528. doi: 10.1185/03007990902920731.
    1. Krajnik M., Zylicz Z., Finlay I., Luczak J., van Sorge A.A. Potential uses of topical opioids in palliative care—Report of 6 cases. Pain. 1999;80:121–125. doi: 10.1016/S0304-3959(98)00211-5.
    1. Inui N., Kato D., Uchida S., Chida D., Takeuchi K., Kimura T., Watanabe H. Novel Patch for Transdermal Administration of Morphine. J. Pain Symptom Manag. 2012;44:479–485. doi: 10.1016/j.jpainsymman.2011.10.022.
    1. Maniar K.H., Jones I.A., Gopalakrishna R., Vangsness C.T., Jr. Lowering side effects of NSAID usage in osteoarthritis: Recent attempts at minimizing dosage. Expert Opin. Pharmacother. 2017;14:1–10. doi: 10.1080/14656566.2017.1414802.
    1. Hans G., Sabatowski R., Binder A., Boesl I., Rogers P., Baron R. Efficacy and tolerability of 5% lidocaine medicated plaster for the topical treatment of post–herpetic neuralgia: Results of long-term study. Curr. Med. Res. Opin. 2009;5:1295–1305. doi: 10.1185/03007990902901368.
    1. Price R.C., Gandhi W., Nadeau C., Tarnavskiy R., Qu A., Fahey E., Stone L., Schweinhardt P. Characterization of a novel capsaicin/heat ongoing pain model. Eur. J. Pain. 2018;22:370–384. doi: 10.1002/ejp.1126.
    1. Baron R., Treede R.D., Birklein F., Cegla T., Freynhagen R., Heskamp M.L., Kern K.U., Maier C., Rolke R., Seddigh S., et al. Tretment of painful radiculopathies with capsaicin 8% cutaneous patch. Curr. Med. Res. Opin. 2017;33:1401–1411. doi: 10.1080/03007995.2017.1322569.
    1. Knezevic N.N., Tverdohleb T., Nikibin F., Knezevic I., Candido K.D. Management of chronic neuropathic pain with single and compounded topical analgesics. Pain Manag. 2017;7:537–558. doi: 10.2217/pmt-2017-0020.
    1. Finnerup N.B., Attal N., Haroutounian S., McNicol E., Baron R., Dworkin R.H., Gilron I., Haanpää M., Hansson P., Jensen T.S., et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015;14:162–173. doi: 10.1016/S1474-4422(14)70251-0.
    1. Sandig A.G., Compmany A.C., Campos F.F., Villena M.J., Naveros B.C. Transdermal delivery of imipramine and doxepin from newly oil-in-water nanoemulsion for an analgesic and anti-allodynic activity: Development, characterization and in vivo evaluation. Colloids Surf. B Biointerfaces. 2013;103:558–565. doi: 10.1016/j.colsurfb.2012.10.061.
    1. Lauretti G.R., Perez M.V., Reis M.P. Double-blind evaluation of transdermal nitroglycerine as an adjuvant to oral morphine for cancer pain management. J. Clin. Anesth. 2002;14:83–86. doi: 10.1016/S0952-8180(01)00360-9.
    1. Campbell C.M., Kipnes M.S., Stouch B.C., Brady K.L., Kelly M., Schmidt W.K., Petersen K.L., Rowbotham M.C., Campbell J.N. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153:1815–1823. doi: 10.1016/j.pain.2012.04.014.
    1. Wrzosek A., Woron J., Dobrogowski J., Jakowicka-Wordliczek J., Wordliczek J. Topical clonidine for neuropathic pain. Cochrane Database Syst. Rev. 2015;8:CD 010967. doi: 10.1002/14651858.CD010967.pub2.
    1. Pergolizzi J.V., Jr., Lequang J.A., Taylor R., Jr., Raffa R.B., Colucci D., NEMA Research Group The role of cannabinoids in pain control: The good, the bad, and the ugly. Minerva Anestesiol. 2018 doi: 10.23736/S0375-9393.18.12287-5.
    1. Lötsch J., Weyer-Menkhoff I., Tegeder I. Current evidence of cannabinoid–based analgesia obtained in preclinical and human experimental settings. Eur. J. Pain. 2017 doi: 10.1002/ejp.1148.
    1. Pickering G., Martin E., Tiberghien F., Delorme C., Mick G. Localized neuropathic pain: An expert consensus on local treatments. Drug Des. Dev. Ther. 2017;11:2709–2718. doi: 10.2147/DDDT.S142630.
    1. Malec-Milewska M. Topical administration of drugs in pain treatment. In: Dobrogowski J., Wordliczek J., Woron J., editors. Pharmacotherapy of Pain. Termedia; Poznan, Poland: 2014. pp. 223–239. (In Polish)

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren